Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6364MR)

This product GTTS-WQ6364MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6364MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ90MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ13183MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ3536MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ6750MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ4877MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ15616MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ15100MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ10190MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW